



Ferriprox® (deferiprone) – First-time generic

- On September 18, 2020, Taro launched an [AB-rated](#) generic version of Chiesi's [Ferriprox \(deferiprone\)](#) 500 mg tablets.
- Ferriprox is approved for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.
- Ferriprox is also available as a brand [1,000 mg tablet](#) and [oral solution](#).
 - Both these formulations carry the same indication as Ferriprox 500 mg tablets.
- Ferriprox carries a boxed warning for agranulocytosis and neutropenia.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.